CancerNetwork® sat down with Sara A. Hurvitz, MD, at the 2021 ASCO Annual Meeting to talk about multidisciplinary care with geriatrician oncologists and the use of age-based analyses for diagnosis and following up of metastatic triple-negative breast cancer.
Patients with metastatic TNBC treated with sacituzumab govitecan maintained an efficacy benefit compared with physician's choice chemotherapy.
Some improvement in pathological complete response may be possible with SD-101 plus pembrolizumab and paclitaxel in certain patients with HER2-negative breast cancer, but results are still uncertain.
Patients with early-stage breast cancer who have ultralow risk disease indicated by a 70-gene signature demonstrated an excellent survival prognosis regardless of clinical risk.
Phase 2 results presented during the 2021 ASCO Annual Meeting suggest durvalumab plus chemotherapy as neoadjuvant therapy for triple-negative breast cancer may be beneficial in certain patients.
With a de-escalation strategy for administration of trastuzumab and pertuzumab in the neoadjuvant setting, patients with HER2-positive, hormone receptor–negative breast cancer experienced high rates of response and survival.
Ribociclib (Kisqali) plus fulvestrant (Faslodex) maintained significantly improved overall survival (OS) rates after nearly 5 years of follow-up compared to fulvestrant alone in postmenopausal patients who had hormone receptor (HR)-postivie, HER2-negative advanced breast cancer.
Venetoclax plus fulvestrant did not result in better outcomes compared to fulvestrant alone in previously treated patients who had locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer.
Palbociclib plus fulvestrant maintained a clinically meaningful overall survival improvement compared to placebo plus fulvestrant after a median follow-up of 73.3 months in patients with HR-positive, HER2-negative advanced breast cancer.
Data from the OlympiA trial support olaparib use in certain patients with BRCA1/2–positive early breast cancer.